(UroToday.com) In this presentation, Dr. Theodora Potretzke discussed several core messages surrounding the use of contrast with imaging for renal cell carcinoma (RCC) patients. Her major points are summarized as: (1) the risk of contrast-induced acute kidney injury from IV iodinated contrast is lower than previously thought, (2) contrast-enhanced MRI using group 2 gadolinium-based contrast agents may be performed without renal function screening, and (3) there are recently published radiology-nephrology consensus statements1,2 to guide the use of contrast with MRI and CT scans in this context.